Windsor Group LTD lessened its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,568 shares of the company’s stock after selling 126 shares during the quarter. Windsor Group LTD’s holdings in AbbVie were worth $2,511,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also added to or reduced their stakes in ABBV. Goepper Burkhardt LLC increased its position in shares of AbbVie by 1.9% in the 4th quarter. Goepper Burkhardt LLC now owns 3,506 shares of the company’s stock valued at $567,000 after purchasing an additional 67 shares during the last quarter. Naviter Wealth LLC increased its position in shares of AbbVie by 0.9% in the 1st quarter. Naviter Wealth LLC now owns 7,378 shares of the company’s stock valued at $1,176,000 after purchasing an additional 68 shares during the last quarter. Sax Wealth Advisors LLC increased its position in shares of AbbVie by 0.9% in the 4th quarter. Sax Wealth Advisors LLC now owns 7,633 shares of the company’s stock valued at $1,233,000 after purchasing an additional 70 shares during the last quarter. 1900 Wealth Management LLC increased its position in shares of AbbVie by 2.8% in the 4th quarter. 1900 Wealth Management LLC now owns 2,631 shares of the company’s stock valued at $425,000 after purchasing an additional 71 shares during the last quarter. Finally, Syntal Capital Partners LLC increased its position in shares of AbbVie by 0.9% in the 3rd quarter. Syntal Capital Partners LLC now owns 7,811 shares of the company’s stock valued at $1,048,000 after purchasing an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 68.27% of the company’s stock.
Insider Activity at AbbVie
In related news, SVP Elaine K. Sorg sold 6,130 shares of the firm’s stock in a transaction dated Tuesday, April 25th. The shares were sold at an average price of $165.00, for a total value of $1,011,450.00. Following the completion of the sale, the senior vice president now owns 35,330 shares in the company, valued at $5,829,450. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Elaine K. Sorg sold 7,499 shares of AbbVie stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $161.67, for a total transaction of $1,212,363.33. Following the completion of the sale, the senior vice president now directly owns 35,330 shares in the company, valued at $5,711,801.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Elaine K. Sorg sold 6,130 shares of AbbVie stock in a transaction dated Tuesday, April 25th. The stock was sold at an average price of $165.00, for a total transaction of $1,011,450.00. Following the sale, the senior vice president now owns 35,330 shares of the company’s stock, valued at $5,829,450. The disclosure for this sale can be found here. Company insiders own 0.26% of the company’s stock.
Wall Street Analyst Weigh In
AbbVie Stock Up 1.1 %
ABBV stock opened at $134.73 on Monday. AbbVie Inc. has a one year low of $130.96 and a one year high of $168.11. The stock has a market capitalization of $237.70 billion, a PE ratio of 31.85, a price-to-earnings-growth ratio of 2.42 and a beta of 0.58. The company has a debt-to-equity ratio of 4.46, a quick ratio of 0.82 and a current ratio of 0.96. The company has a fifty day moving average of $142.20 and a 200-day moving average of $150.86.
AbbVie (NYSE:ABBV – Free Report) last released its earnings results on Thursday, April 27th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. AbbVie had a net margin of 13.37% and a return on equity of 153.92%. The company had revenue of $12.23 billion during the quarter, compared to analysts’ expectations of $12.23 billion. During the same quarter last year, the business earned $3.16 EPS. The business’s revenue was down 9.7% on a year-over-year basis. As a group, analysts expect that AbbVie Inc. will post 10.99 EPS for the current year.
AbbVie Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be paid a $1.48 dividend. This represents a $5.92 annualized dividend and a dividend yield of 4.39%. The ex-dividend date is Thursday, July 13th. AbbVie’s dividend payout ratio (DPR) is presently 139.95%.
AbbVie Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.
Featured Stories
- Five stocks we like better than AbbVie
- MarketBeat Week in Review – 6/26 – 6/30
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
